In a report issued on August 3, Yatin Suneja from SunTrust Robinson reiterated a Buy rating on Global Blood Therapeutics (NASDAQ: GBT), with a price target of $70. The company’s shares closed on Friday at $46.55.
According to TipRanks.com, Suneja is a 3-star analyst with an average return of 4.3% and a 49.2% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Seattle Genetics, La Jolla Pharma, and AnaptysBio Inc.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $84.13, representing an 80.7% upside. In a report issued on July 25, William Blair also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
Based on Global Blood Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $40.37 million. In comparison, last year the company had a GAAP net loss of $23.88 million.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
